TITLE

Prostate cancer vaccines: Update on clinical development

AUTHOR(S)
Geary, Sean M.; Salem, Aliasger K.
PUB. DATE
May 2013
SOURCE
OncoImmunology;May2013, Vol. 2 Issue 5, pe24523-1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Prostate cancer is a common malignancy among elderly men and is essentially incurable once it becomes metastatic. Results from clinical trials testing a panel of specific vaccines in patients with castration-resistant prostate cancer (CRPC) suggest that alternative therapies may one day substitute or support the current gold standard (docetaxel plus prednisone). Here, we summarize the results of germane clinical trials completed during the last 12 y and provide updates on some currently ongoing studies. As it stands, prostate cancer vaccines appear to be safe and capable of generating prostate-specific T lymphocyte responses with potential antitumor activity.
ACCESSION #
87741412

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics